AI-native pharma company, bringing new treatments to patients faster and more efficiently.
New York, NY
Joined November 2014
- Tweets229
- Following30
- Followers2.4K
- Likes107
(1/3) Phyla is Formation Bio’s context layer for causal biology. We benchmarked it against Claude Science and GPT-Rosalind on writing full research dossiers for 7 drug target–disease pairs, and the results are in. 99.7% of Phyla’s statements carried a citation, compared to Claude Science: 87% (Claude Science) and 86% (GPT-Rosalind). Phyla never dropped below 99.3% on any pair.
(2/3) In an audit of claims, Phyla led on every target-disease pair. 92% of Phyla’s claims were fully backed by the source it cited, vs. 80% (Claude Science) and 67% (GPT-Rosalind).
(3/3) Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. When asked a plain language question, Phyla pulls the gene record, checks clinical precedent, computes tissue-specific expression, and runs mechanistic analysis over the results — returning an answer with every claim traced to a source. Here’s how we built it, and how it’s used at Formation: formation.bio/blog/phyla
Phyla aggregates 90 tools across 27 biomedical sources and ties every single claim to a checkable citation. Benchmarked against two other frontier AI life-science platforms, writing full research dossiers across 7 target–disease pairs: 99.7% of Phyla’s statements carried a citation (vs. 87% and 86%), and 92% of its claims were fully backed by the cited source (vs. 80% and 67%). See how we built it, and how it’s being used at Formation: formation.bio/blog/phyla
“As a company in the era of AI, you should have a thesis for what predictions will happen first, what will happen last, and make sure your company strategy absorbs this as a net tailwind versus a headwind.”
Our thesis: AI will improve drug discovery first, toxicity next, and clinical efficacy last. Our CEO @BenjamineYLiu explores this in his Uneven Frontiers essay – link in comments.
Formation Bio made #7 on @FastCompany's Best Workplaces for Innovators 2026.
This piece highlights one of our internal systems: ARK (AI-ready Repository of Knowledge), our in-house AI platform that connects all internal systems and data across the company. Full write-up here: fastcompany.com/91591991/for…
Our open roles: formation.bio/careers
Learn more about ARK: formation.bio/blog/ark-mcp-g…
Proud to be selected as #7 on @FastCompany's 2026 100 Best Workplaces for Innovators, plus as a winner on the Biotech, Healthcare & Life Sciences list.
Find us on the full list: fastcompany.com/best-workpla…
We're hiring across New York and Boston now: formation.bio/careers
Our CEO @BenjamineYLiu recently sat down with @LanceGlinn on @NYSE's Inside the ICE House to talk about how and why Formation Bio is tackling the drug development bottleneck, a problem that is only set to grow as the number of drugs at the top of the funnel increases. Links to listen in comments:
Hear from @formationbio co-founder & CEO Ben Liu on @ICEHousePodcast where he talks about...
- Bottleneck's slowing down drug development
- AI's impact on drug discovery
- Bringing new medicines to patients
Spotify: open.spotify.com/episode/60l…
YouTube: youtu.be/DaN84yEwBvU?si=tOHz…
Formation Bio retweeted
"In a world of drug discovery abundance, the scarce capability is no longer making drugs, but rather, knowing which drugs are worth developing."
@BenjamineYLiu, co-founder and CEO of Formation Bio, explains how AI will transform the economics of the pharma industry - link in replies
What drew Mike Ehlers, our new Chief Scientific Officer and Head of R&D, to Formation Bio? Hear it in his own words.
More on Mike’s life outside the lab in today’s @statnews executive moves column: statnews.com/pharmalot/2026/…
In his latest blog, our Principal Engineer Kenny Peng revisits the Unix philosophy (do one thing well, compose freely, shared interfaces) as a blueprint for agentic system design.
Using biopharma as the test case, he breaks down why hardcoded pipelines break down over time, and what composable alternatives require. Read here: linkedin.com/posts/kpeng_the…
Formation Bio retweeted
.@BenjamineYLiu has raised more than $600M for his AI-native biopharma company - and he's hiring!
@formationbio is applying AI to drug development, with a mission to bring new treatments to patients faster and more efficiently.
The team is hiring across the board, including:
- Director, Brand & Communications
- Senior Director or VP, Product
- General Manager (Drug Asset Lead)
- Principal Data Scientist, Medical Imaging
- Data Scientist, Portfolio Optimization
- Director, Business Development - Search & Evaluation
Full story + list of open roles in thread!
Formation Bio retweeted
Formation Bio said it has appointed former Biogen research head Michael Ehlers as its chief scientific officer, bringing a seasoned drug and biotech veteran into the AI-focused health startup. bloomberg.com/news/articles/…
Formation Bio retweeted
Excited to share that Mike Ehlers is joining @formationbio as Chief Scientific Officer and Head of R&D. Over the course of his career as a scientist, drug developer, and investor, Mike has advanced 40+ drugs into the clinic, with approvals spanning Alzheimer's, ALS, MS, hemophilia, and SMA. Welcome to the team, Mike!
The @decodingbio AI x Bio Summit lands in NYC this week, and our CEO and Co-Founder @BenjamineYLiu will be speaking at the @awscloud Executive Reception that follows, joining a panel on what it takes to scale AI in pharma.
Read more and request to join: luma.com/iylrgtia
This Thursday, our Co-Founder & CEO @BenYLiu takes the stage at @decodingbio's AI x Bio Summit at the @NYSE to discuss how platform companies are creating new business models in biotech – alongside voices from @Nabla Bio, @Manifold Bio, and @Dimension Capital. Link to register: events.decodingbio.com/summi…
